
| Pair Name | Mangiferin, Cisplatin | ||
| Phytochemical Name | Mangiferin (PubChem CID: 5281647 ) | ||
| Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Drug Name | Cisplatin |
| Adverse Reactions | Myelosuppression, dry mouth and throat, fever, dry stools. This was inferred hot nature anticancer drug. |
| Recommendations | Cold: Anemarrhena asphodeloides; Urena lobataL; Artemisia scoparia; Swertia mussotii; Swertia pseudochinensis; Gentiana manshurica; Gossampinus malabarica; Pyrrosia sheareri; Pyrrosia sheareri; Iris domestica; Gentiana scabra; Pyrrosia sheareri; Pyrrosia petiolosa |
| Reference | ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899. ref_link |
| Pair Name | Mangiferin, Cisplatin | |||
| Disease Info | Nephrotoxicity | Investigative | ||
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | NFE2L2 | hsa4780 |
| Up-regulation | Expression | BAX | hsa581 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Expression | MYC | hsa4609 | |
| Down-regulation | Cleavage | CASP3 | hsa836 | |
| Down-regulation | Expression | CAPN1 | hsa823 | |
| Down-regulation | Cleavage | CASP12 | hsa100506742 | |
| Up-regulation | Expression | PIK3CA | hsa5290 | |
| Up-regulation | Expression | HMOX1 | hsa3162 | |
| Up-regulation | Expression | SOD2 | hsa6648 | |
| In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
| SK-RC-45 | Clear cell renal cell carcinoma | Homo sapiens (Human) | CVCL_4016 | |
| EAC-E2G8 | Malignant neoplasms of the mouse mammary gland | Mus musculus (Mouse) | CVCL_WJ08 | |
| In Vivo Model | Four weeks old male swiss albino mice were used for this study. | |||
| Result | The study reveals a mechanistic basis of mangiferin action against cisplatin induced nephrotoxicity. Since Mangiferin shows synergistic anticancer activity with cisplatin, it can be considered as a promising drug candidate, to be used in combination with cisplatin. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Mangiferin Ameliorates Cisplatin Induced Acute Kidney Injury by Upregulating Nrf-2 via the Activation of PI3K and Exhibits Synergistic Anticancer Activity With Cisplatin. Front Pharmacol. 2018 Jun 18;9:638. doi: 10.3389/fphar.2018.00638. | Click |